Biotech · Private company
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Track this companyFree. Adds Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation to your Dealase workspace and tells you when its record changes.
Clinical trials60 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials6
- A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsPHASE1 · COMPLETED · started Jan 12, 2021ClinicalTrials.gov NCT04702464 · fetched Nov 12, 2026
- Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and MetforminPHASE1 · COMPLETED · started Dec 18, 2019ClinicalTrials.gov NCT04231435 · fetched Nov 12, 2026
- A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic ImpairmentPHASE1 · COMPLETED · started Sep 4, 2019ClinicalTrials.gov NCT03983161 · fetched Nov 12, 2026
- Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsPHASE1 · COMPLETED · started Jun 21, 2019ClinicalTrials.gov NCT03983239 · fetched Nov 12, 2026
- A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibPHASE3 · TERMINATED · started Mar 27, 2019ClinicalTrials.gov NCT03755518 · fetched Nov 12, 2026
- Individual Patient Compassionate Use of FedratinibAVAILABLEClinicalTrials.gov NCT03723148 · fetched Nov 12, 2026